Compare IFS & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFS | IMVT |
|---|---|---|
| Founded | 1897 | 2018 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.0B |
| IPO Year | 2014 | 2019 |
| Metric | IFS | IMVT |
|---|---|---|
| Price | $46.43 | $23.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $48.00 | $30.78 |
| AVG Volume (30 Days) | 224.2K | ★ 916.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.09 | $12.72 |
| 52 Week High | $52.58 | $29.25 |
| Indicator | IFS | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 32.65 |
| Support Level | $38.93 | $21.74 |
| Resistance Level | $52.00 | $24.63 |
| Average True Range (ATR) | 1.64 | 1.07 |
| MACD | -0.08 | -0.33 |
| Stochastic Oscillator | 52.68 | 1.68 |
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.